Dr. Chatterjee’s Laboratories (DCL) is an early-stage wireless healthcare technology company that is developing smartphone and sensor-based, in-home wireless monitoring technologies to assist chronic older adult patients with a primary focus in Type-2 diabetes. The technology platform is based on the patented Persuasive Sensing Technology (PST) which provides an easy architecture to monitor activity of daily living from ambient sensors as well as body-wearable sensors, process and mine vital data through advanced algorithms, and then generates daily text messages and tailored health newsletter to alter health behavior and achieve better patient compliance and wellbeing. Our AI-based predictive software (PME) can predict which patient needs hospital readmission thereby saving costs for healthcare providers. The technology serves as a continuous virtual patient-coach educating them to better manage their diabetes condition. Our software analytics platform is unique as it has the potential to be used in other chronic disease monitoring areas such as congestive heart failure (CHF).
DCL emerged from over 10 years of R&D conducted by Prof. Chatterjee and his team at Claremont Graduate University. The initial prototypes were developed with a grant from the National Science Foundation.
DCL emerged from over 10 years of R&D conducted by Prof. Chatterjee and his team at Claremont Graduate University. The initial prototypes were developed with a grant from the National Science Foundation.